Imedex® is an industry leader in providing certified, independent continuing medical education to health care professionals.

21-23 April 2017

Prague, Czech Republic

New Perspectives in Myelofibrosis Treatment

Symposium at the 2017 European Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes Congress, certified for continuing medical education credit by Imedex

22 April 2017
InterContinental Praha
Prague, Czech Republic

Symposium Chair

Tiziano Barbui, MD
Research Foundation Ospedale Maggiore
Bergamo, Italy

Myelofibrosis (MF) is a complex disease that is challenging to treat and can potentially progress into acute leukemia, threatening mortality and profoundly affecting the quality of life of patients. Major advances have been made in the treatment of this disease including the introduction of JAK inhibitors. Due to the treatment complexity of patients with MF, international experts in MF will address the mechanisms of action and targets of current and emerging agents for the treatment of MF, evaluate the results from clinical trials investigating the safety and efficacy of current and emerging agents, and demonstrate how to individualize treatment for patients with MF during this educational activity.

Continuing Education

ACCMEImedex®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex®, LLC designates this live educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Maintenance of Certification (MOC)
Successful completion of this CME activity enables a participant to earn up to 1.5 MOC points towards the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is Imedex's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC Points.

Who Should Attend
This educational activity is designed to meet the educational needs of hematologists and other health care professionals who manage patients with myelofibrosis.

Objectives
Upon successful completion of this educational activity, participants should be able to:

  • Analyze clinical trial data regarding safety and efficacy factors of current and emerging therapies for myelofibrosis
  • Identify treatment regimens for patients with MF, including combination therapy, based on mechanism of action, efficacy, and safety of current and emerging agents
  • Elucidate strategies to assess and manage adverse effects for current and emerging MF therapies for optimal patient outcomes
  • Utilize risk assessment tools, such as the Dynamic International Prognostic Scoring System (DIPSS), and molecular profiles to aid in individualizing therapy for patients with MF

Faculty

Tiziano Barbui, MD
Research Foundation Ospedale Maggiore
Bergamo, Italy

Martin Griesshammer, MD, PhD
Johannes Wesling Medical Center Minden
UKRUB, University of Bochum
Minden, Germany

Claire Harrison, DM, FRCP, FRCPath
Guy's and St Thomas' NHS Foundation Trust
London, United Kingdom

Agenda

12:30 pm

Introduction & Pre-survey
Tiziano Barbui, MD

12:40 pm

New insight in pathology and prognosis of myelofibrosis
Tiziano Barbui, MD

12:55 pm

Clinical trial data supporting the safety and efficacy profiles for current and emerging agents
Claire Harrison, DM, FRCP, FRCPath

13:10 pm

Optimizing treatment strategies: Managing adverse effects and optimizing efficacy of agents in myelofibrosis
Martin Griesshammer, MD, PhD

13:25 pm

Panel discussion: Utilizing the Dynamic International Prognostic Scoring System (DIPSS) to formulate strategies for individualized therapy
Moderator: Tiziano Barbui, MD

13:40 pm

Summary & questions

13:55 pm

Post-survey

14:00 pm

Adjourn

Support

The following company has provided an educational grant in support of this symposium:

Novartis Pharmaceuticals Corporation

Registration

Registration is complimentary! Please remember to bring your Badge. Space is limited and available on a first come first serve basis.

Important Dates

Early Registration Deadline 20 April 2017
Presentation Dates 22 April 2017


The Registration and Information Desk in the Congress Hall will be staffed:

Saturday, 22 April 2017 8:00 – 17:00

Organizer


11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
Web: www.imedex.com
FacebookTwitterLinkedInEmail

For registration inquiries:               

Tel.: +1 (800) 233 0957 
Direct: +1 (678) 242 0906
Fax: +1 (678) 242-0920
Email: registration@imedex.com